Monte Rosa Therapeutics Reports Positive Clinical Data for Prostate Cancer Treatment

Key Facts

1MRT-2359 in combination with enzalutamide showed a 100% PSA response rate in patients with androgen receptor mutations.

2The overall disease control rate was 67% across all 15 evaluable patients in the study.

3The company plans to initiate a new Phase 2 study in Q3 2026.

Monte Rosa Therapeutics (Nasdaq: GLUE) announced positive updated Phase 1/2 clinical data for its molecular glue degrader, MRT-2359, targeting metastatic castration-resistant prostate cancer (mCRPC). The study revealed a remarkable 100% PSA response rate in patients with specific androgen receptor mutations when MRT-2359 was combined with enzalutamide. Across the total cohort of 15 evaluable patients, the company reported a disease control rate of 67%, signaling strong efficacy in heavily pretreated cases. These results were presented at the ASCO Genitourinary Cancers Symposium, highlighting the potential of the company's therapeutic platform. Following these encouraging signals, Monte Rosa plans to initiate a new Phase 2 study in the third quarter of 2026. Investors view this clinical progress as a significant validation of the company's pipeline and its ability to address complex oncological challenges.